Digital Pathology-based Artificial Intelligence Biomarker Validation in Metastatic Prostate Cancer.

ABSTRACT:

Background and objective

Owing to the expansion of treatment options for metastatic hormone-sensitive prostate cancer (mHSPC) and an appreciation of clinical subgroups with differential prognosis and treatment responses, prognostic and predictive biomarkers are needed to personalize care in this setting. Our aim was to evaluate a multimodal artificial intelligence (MMAI) biomarker for prognostic ability in mHSPC.

Methods

We used data from the phase 3 CHAARTED trial; 456/790 patients with mHSPC had evaluable digital histopathology images and requisite clinical variables to generate MMAI scores for inclusion in our analysis. We assessed the association of MMAI score with overall survival (OS), clinical progression (CP), and castration-resistant PC (CRPC) via univariable Cox pr

SUBMITTER: Markowski MC 

PROVIDER: S-EPMC12369405 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature